NCT03785535 is a NA clinical trial of Vibrotactile stimulation in Fibromyalgia, sponsored by Neurovoxel SLP.

Who is sponsoring NCT03785535?

NCT03785535 is sponsored by Neurovoxel SLP.

What drugs are being tested in NCT03785535?

Interventions in NCT03785535: Vibrotactile stimulation.

What condition does NCT03785535 study?

NCT03785535 studies Fibromyalgia.

Is NCT03785535 still recruiting?

NCT03785535 is currently completed. Last updated 3 March 2021.

Last reviewed 2021-03-03 · How we verify

NCT03785535

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Functional MRI Study of Vibrotactile Stimulation Effects in Fibromyalgia

Completed NA Last updated 3 March 2021

What this trial tests

NA trial testing Vibrotactile stimulation in Fibromyalgia in 60 participants. Completed in 28 February 2021.

Timeline

15 January 2019

Primary endpoint
28 February 2021

28 February 2021

Quick facts

Lead sponsor	Neurovoxel SLP
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	15 January 2019
Primary completion	28 February 2021
Estimated completion	28 February 2021
Sites	1 location across Spain

Drugs / interventions tested

Vibrotactile stimulation

Conditions studied

Fibromyalgia — all drugs for Fibromyalgia →

Sponsor

Neurovoxel SLP

Who can join

Adults 18 to 65, female only, with Fibromyalgia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the effects of low-intensity and prolonged vibrotactile sensory stimulation on brain activity and functional connectivity in fibromyalgia patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Distinctive alterations in the functional anatomy of the cerebral cortex in pain-sensitized osteoarthritis and fibromyalgia patients.
Pujol J, Blanco-Hinojo L, Doreste A, Ojeda F, et al · · 2022 · cited 10× · PMID 36369217 · DOI 10.1186/s13075-022-02942-3

Verify or expand the search:

Other trials of Vibrotactile stimulation

Trials testing the same drug.

NCT03298243 — Use of Sensory Substitution to Improve Arm Control After Stroke · NA · recruiting
NCT03227952 — Sensory Stimulation in Fibromyalgia · NA · completed
NCT01765673 — The Passy Muir Swallowing Self Training Device · completed

Other recruiting trials for Fibromyalgia

Currently open trials in the same condition.

NCT02285868 — ATI Evidence-based Guide Investigating Clinical Services · active not recruiting
NCT07245303 — Neural Mechanisms of Light Driven Analgesia · NA · recruiting
NCT05901259 — The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes · recruiting
NCT07358754 — The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor · recruiting
NCT07465991 — The Effect of Digital Cognitive Behavioural Therapy for Insomnia on Physical Activity in Fibromyalgia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03785535 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neurovoxel SLP
Last refreshed: 3 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03785535.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing